-
Are Checkpoint Inhibitors Impacting How We Cure Disease?
Throughout September and October, we have been discussing Precision Medicine and it’s impact on various segments of the life sciences. -
Oncology, Rare Diseases, and Regenerative Medicine: Where does Companion Diagnostics fit in each
Moving on from our Precision Medicine in Neurosciences, Kineticos’ Founder and CEO, Shailesh Maingi, talks with a diagnostics expert on -
Partnerships: Is Sharing Better for Precision Medicine in Neuroscience?
Closing out our Precision Medicine in Neurosciences discussion, Nik and Jason discuss how various partnerships can impact the success of -
Biomarkers, Partnerships, and Companion Diagnostics: How will they impact the approval of Neuroscience Drugs?
Continuing our Precision Medicine in Neuroscience discussion, Jason Kralic and Nik Tezapsidis discuss how biomarkers and partnerships will drive precision -
8 Key Principles to Building a Board of Directors
There are too many great ideas that never reach the surface in our industry and that’s where Kineticos’ newest family -
The FDA’s Shift from Gate Keeper to Enabler
Most of us were shocked when Scott Gottlieb stepped down from his duties as the FDA Commissioner. He is largely
The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. Our consulting team has a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting or in industry. Overall the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions.
The Biopharmaceutical Practice at Kineticos supports clients across three service areas including:
Corporate Strategy & Development
- Business Model Design
- Portfolio Strategy
- Geographic Market Entry Strategy
- Opportunity Assessment
- In- and Out- Licensing
- Private Financing
Medical Affairs Strategy
- Medical Affairs Strategic Planning & Operations
- MSL Architecture, Management and Support
- Real World Evidence/Registry Study
Commercial Strategy
- New Product Planning
- Strategic Launch Planning
- Post-Marketing Strategy and Planning
- Lifecycle Management
- Marketing Excellence
Regulatory
- Regulatory Strategy
- Product Development
- Regulatory Operations & Submissions Management
Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog
-
Portfolio Prioritization – Oncology
Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. -
Oncology Commercial Assessment – Melanoma
Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the -
Business Development & Licensing
Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and -
Product Search
Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and -
Commercial Assessment
Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment -
Business Development and Licensing
Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with
-
Growth by Acquisition in Life Sciences: Do You Have a Plan?
Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as -
R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation
James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation? -
Merck KGaA and Bayer Choose Opposite Strategies
Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent -
Foundation Medicine and Clovis Expand Partnership
Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion -
Role of Companion Diagnostics in Immuno-oncology Race Unfolding
Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies -
Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity
Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its